Home / Research Library / Science Explained
Research peptides are short chains of amino acids, usually made by chemical synthesis and supplied as a freeze-dried powder, that are sold for laboratory research rather than as medicines. The "research use only" (RUO) label means the material is intended for in vitro or animal research, has not been evaluated or approved as a medicine, and is not for human or veterinary use, even when the same molecule exists elsewhere as an approved drug.
This primer covers the basics behind every compound in our research library: what a peptide is, where the line between peptides and proteins falls, how peptides are made, why they are freeze-dried, and what the RUO label does and does not mean. It ends with a map of the library.
Peptides are built from amino acids. Each amino acid has an amino group, a carboxyl group and a distinctive side chain, and twenty of them are encoded in the genetic code. When the carboxyl group of one amino acid reacts with the amino group of the next, the two join through a peptide (amide) bond and a molecule of water is released. Repeat that and you get a chain with a free amino group at one end, the N-terminus, and a free carboxyl group at the other, the C-terminus.
Sequences are written from N-terminus to C-terminus, usually in one-letter code. Semax, for example, is MEHFPGP: methionine, glutamic acid, histidine, phenylalanine, proline, glycine, proline (see our Semax research overview). DSIP is WAGGDASGE. Two residues make a dipeptide, three a tripeptide, and a few to a few dozen an oligopeptide or peptide.
The body uses peptides extensively as hormones and signalling molecules, and they have a long history as medicines: since insulin was introduced almost a century ago, more than 80 peptide drugs have reached the market.1
There is no sharp biological boundary. Textbooks often put it at around 50 amino acids, and the practical distinction is that proteins usually fold into stable three-dimensional structures that small peptides do not.
Regulators have had to draw a line. US federal regulations define a protein as any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size; where two or more chains are associated as they occur in nature, their amino acids are counted together.2 Under that definition a chain of 40 or fewer amino acids is a peptide, while a two-chain hormone of 51 residues such as insulin counts as a protein. Most research peptides are far shorter: Semax and Selank have seven residues, DSIP nine.
Short peptides like those in this library are usually made by chemical synthesis rather than extracted from animals or expressed in cells. The dominant method is solid-phase peptide synthesis (SPPS), introduced by Bruce Merrifield in 1963.3 His idea was to anchor the growing chain to an insoluble resin bead so that excess reagents could simply be washed away after each step, which made synthesis faster and open to automation. Merrifield received the 1984 Nobel Prize in Chemistry "for his development of methodology for chemical synthesis on a solid matrix".4
Today the usual chemistry uses the Fmoc protecting group, and Fmoc SPPS has become the method of choice for peptide synthesis; multi-tonne production of therapeutic peptides by the same method has made high-quality building blocks cheap and widely available.5
Each cycle is very efficient but never perfect, and small failures accumulate over a long sequence. A review of impurities in peptide medicines groups the synthesis-related ones as follows.6
| Impurity | What it is | Typical origin |
|---|---|---|
| Deletion sequences | The target peptide missing one amino acid | Inefficient Fmoc removal, so a coupling step is skipped |
| Insertion sequences | The target peptide with an extra amino acid | Excess amino acid reagent |
| Diastereomers | A residue with the wrong handedness (racemisation) | Side reactions during deprotection |
| Protection adducts | Side-chain protecting groups left attached | Incomplete deprotection |
| Oxidation products, dimers and oligomers | Modified or linked copies of the peptide | Side-chain oxidation; peptide molecules joining together |
| Counter-ions such as trifluoroacetate | Salt partners carried into the final powder | The synthesis itself or later purification steps |
The same review notes that such impurities can distort early functional studies and lead to wrong conclusions.6 That is why purity and identity data matter to researchers; see how HPLC and mass spectrometry test peptide purity and how to read a certificate of analysis.
A vial of peptide powder is never 100% peptide. Charged side chains and termini carry counter-ions, such as trifluoroacetate left over from synthesis and purification or acetate introduced by exchanging it, and the powder holds some residual water.6 The fraction of the powder that is actually peptide is called the net peptide content, and it is lower than the gross weight. Purity, by contrast, describes what share of the peptide material is the intended sequence rather than related impurities. The two numbers answer different questions, and molar calculations in the lab should account for both.
Lyophilisation, or freeze-drying, removes water from a frozen product without melting it. The solution is frozen; in primary drying, the pressure is lowered so the ice sublimes directly to vapour; in secondary drying, the temperature is raised to drive off water still bound to the solid. What is left is a dry, porous cake or powder.
The reason is stability. In solution, peptides and proteins are exposed to water-driven degradation, and lyophilisation is the most commonly used method for preparing solid protein pharmaceuticals. It is not stress-free: freezing and drying can themselves damage proteins, and even dried products have limited long-term stability.7 Peptide-specific degradation routes include beta-elimination and the formation of diketopiperazines, pyroglutamate and succinimide.6
In practice, a lyophilised peptide is kept cold, dry and away from light, and is reconstituted only when needed. Our guides cover storing lyophilised and reconstituted peptides and reconstitution with bacteriostatic or sterile water.
The phrase comes from US medical-device regulation. In vitro diagnostic products that are still in the laboratory research phase must carry the statement "For Research Use Only. Not for use in diagnostic procedures."8 Similar wording is now widely used on laboratory reagents and research chemicals.
On a peptide, an RUO label communicates that the material:
What the label does not do is change a substance's legal status. Under Australia's Therapeutic Goods Act 1989, therapeutic goods are goods that are represented in any way to be, or are likely to be taken to be, for therapeutic use.9 How a product is presented and promoted therefore matters, not just the words on the vial. Scheduling applies regardless of labelling too: the June 2026 Poisons Standard names several peptides that are also sold as research compounds in Schedule 4 (prescription only medicines), and lists some of them in Appendix D, clause 5, among poisons that must not be possessed without authority.10 Our article on whether research peptides are legal in Australia explains the framework.
Nor is RUO a quality grade. It says nothing about purity, identity or content; those are documented, if at all, in a certificate of analysis.
| Approved peptide medicine | Research peptide (RUO) | |
|---|---|---|
| Intended use | Use in patients, within approved indications | Laboratory research: in vitro and animal studies |
| Regulatory assessment | Evaluated by a regulator such as the TGA or FDA for quality, safety and efficacy | Not evaluated as a medicine |
| Evidence behind it | Clinical trials in humans | None required for sale as a research material |
| Labelling | Product information with indications and dosing for prescribers | Research use only; not for human or veterinary use; no dosing |
The same molecule can sit on both sides of this table. A research-grade version of a compound that is also an approved drug is not that approved medicine: it has not been made or assessed to the medicine's standard, and it carries none of its approvals.
Every article in our library applies the principles above to a specific compound or lab task, with the model, sample size and study type stated for each finding.
| Topic | Articles |
|---|---|
| Peptides studied in injury and wound models | BPC-157: what the research says; TB-500 and thymosin beta-4; BPC-157 vs TB-500 compared; GHK-Cu copper peptide |
| Metabolic and endocrine peptides | Retatrutide, the triple agonist; incretin agonists compared; tesamorelin, a GHRH analogue; MOTS-c, a mitochondrial-derived peptide |
| Neuropeptide analogues | Semax; Selank; Semax vs Selank compared; DSIP, delta sleep-inducing peptide |
| Melanocortin receptor agonists | PT-141 (bremelanotide) |
| Lab handling | Storing peptides; reconstitution with bacteriostatic water; reading a certificate of analysis; HPLC and mass spectrometry purity testing |
| Regulation | Are research peptides legal in Australia?; peptides and the WADA Prohibited List |
Titan Peptides supplies its peptide catalogue for laboratory research only.
They are used in laboratory research: cell culture experiments, biochemical and binding assays, animal models and as analytical reference materials. Research peptides are not medicines. They carry a research-use-only label, have not been evaluated by a regulator for human use, and are not supplied for human or veterinary use.
It means the material is intended for laboratory research, has not been manufactured, tested or approved as a medicine, and is not for human or veterinary use. The wording comes from US regulations for in vitro diagnostics in the research phase. It is not a quality grade and does not change a substance's legal status.
It depends on the substance and how it is presented. Goods represented as, or likely to be taken to be, for therapeutic use are therapeutic goods under the Therapeutic Goods Act 1989, whatever the label says, and some peptides are named in Schedule 4 of the Poisons Standard. Our Australian legal guide covers the detail.
No. A prescription peptide medicine has been evaluated by a regulator for quality, safety and efficacy and comes with approved indications and dosing. A research peptide has not been assessed as a medicine, even when it is the same molecule as an approved drug, and it is supplied for laboratory research only.
They are lyophilised, or freeze-dried. The peptide solution is frozen and the ice is removed under vacuum by sublimation, leaving a dry cake or powder. Removing water slows many degradation reactions, so the dried form keeps better than a solution. It is reconstituted in a suitable solvent only when needed.
Most are made by solid-phase peptide synthesis. The first amino acid is anchored to a resin bead and the chain is built one protected amino acid at a time, with washing after each step. The finished peptide is cleaved from the resin with acid, purified by HPLC, checked by mass spectrometry and freeze-dried.
What the TGA, the June 2026 Poisons Standard, the Therapeutic Goods Act and customs law actually say about peptides, "research use only" labels, importing and advertising in Australia.
A laboratory guide to storing lyophilised and reconstituted peptides: freezer temperatures, moisture, oxidation-prone residues, light, freeze–thaw cycles and adsorption to containers.
How reverse-phase HPLC and mass spectrometry are used to test peptide purity and identity, how to read a chromatogram and a mass spectrum, and what each method cannot tell you.
